Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement.

Since 2020, we’ve seen a clear split: assets averaging a 2.6 in Uncertainty & Sensitivity tend to glide through HTA evaluations, while those around 2.0 invite “wait-and-see” rulings or restricted coverage due to lingering doubt. That 0.6-point difference often determines whether payers trust your read of the evidence—or push for more data.

At MARA Rating, we convert uncertainty and context from NICE (UK), G-BA/IQWiG (Germany), and ICER (US)into a clean A++ to C score—now spanning 350+ assets. This domain reflects the “residual wiggle room” in your evidence and its broader system effects.

What the Uncertainty & Sensitivity Domain Covers

It evaluates how stable and complete your evidence base is—and the context HTA bodies care about:

• Uncertainty & Sensitivity Analysis: Were key results stress-tested under alternative assumptions? Are confidence intervals narrow or wide?
• Equity & Access Considerations: Does the therapy disproportionately benefit advantaged subgroups, or does it close an unmet-need gap for underserved populations?
• Broader System Impacts: Potential upsides (productivity, caregiver relief) and risks (ethical concerns, equity issues, political pressure).

What Strong vs. Marginal Looks Like

• A++ / A+ / A (“Strong or above”): These assets averaged ≥2.6. Sensitivity testing delivered stable outcomes, and context (unmet need, equity uplift) strengthened payer confidence.
• B++ to C (“Marginal or below”): Assets at ≤2.0 ran into cautious or negative HTA outcomes—uncertainty in long-term effects, volatile models, or ethical red flags drove conditional coverage or outright rejection.

Even a 0.1-point step-up can shift a “conditional approval” to a “full endorsement.”

Actionable Moves by Role

• Market Access: Build comprehensive sensitivity analyses into the dossier. Showcase stable base-case results and predefine follow-up data plans to tackle long-term unknowns.
• Investors & Acquirers: Favor assets with robust scenario testing and strong contextual narratives—those that mitigate equity/ethical concerns carry less risk.
• Drug Developers: Design subgroup and system-impact studies early. Demonstrate how your therapy addresses unmet need or reduces caregiver burden, and head off potential societal objections.

Find Your Edge

Our anonymized distributions across 350+ assets pinpoint where your uncertainty profile sits—and where to shore up confidence.

Curious how your product scores? Visit mararating.com or drop us a line.

#MarketAccess #HTA #EvidenceStrategy #Uncertainty #MARARating #MarketAccessScore